It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia

April 20, 2016

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of novel small molecule oncology therapeutics, announced on April 19 that it has entered into a clinical collaboration with Genentech.

The collaboration will evaluate the potential for combining Astex's next-generation hypomethylating agent, guadecitabine (SGI-110), with Genentech's investigational anti-PD-L1 monoclonal antibody, atezolizumab, in the treatment of acute myeloid leukemia (AML). An initial Phase 1b study will investigate the safety and pharmacology of the combination.

For more information about Astex Pharmaceuticals, please visit http://www.astx.com


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases